Literature DB >> 18318133

[Evaluation of the efficacy of wiferon and arbidol in adult influenza].

L V Kolobukhina, V V Malinovskaia, R Z Gatich, L N Merkulova, E I Burtseva, E I Isaeva, O V Parshina, T S Guseva, T G Orlova, F V Voronina.   

Abstract

The therapeutic efficacy of wiferon (recombinant alpha2beta-interferon) versus arbidol was studied in a double-blind controlled study in patients with laboratorily verified influenza. Within the first 24-36 hours after the onset of the disease, wiferon and arbidol reduced the duration of fever, intoxication, and the catarrhal symptoms of the disease as a whole. The agents were shown to have an immunomodulating effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318133

Source DB:  PubMed          Journal:  Vopr Virusol        ISSN: 0507-4088


  4 in total

Review 1.  Arbidol as a broad-spectrum antiviral: an update.

Authors:  Julie Blaising; Stephen J Polyak; Eve-Isabelle Pécheur
Journal:  Antiviral Res       Date:  2014-04-24       Impact factor: 5.970

2.  Modeling the Structure-Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein.

Authors:  Matthew R Freidel; Roger S Armen
Journal:  J Chem Inf Model       Date:  2021-12-13       Impact factor: 6.162

Review 3.  Characteristics of human infection with avian influenza viruses and development of new antiviral agents.

Authors:  Qiang Liu; Dong-Ying Liu; Zhan-Qiu Yang
Journal:  Acta Pharmacol Sin       Date:  2013-10       Impact factor: 6.150

4.  Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.

Authors:  Ming-Yan Liu; Shuang Wang; Wei-Fan Yao; Hui-zhe Wu; Sheng-Nan Meng; Min-Jie Wei
Journal:  Clin Ther       Date:  2009-04       Impact factor: 3.393

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.